JP2024010704A - 血液透析用の透析液 - Google Patents
血液透析用の透析液 Download PDFInfo
- Publication number
- JP2024010704A JP2024010704A JP2022112133A JP2022112133A JP2024010704A JP 2024010704 A JP2024010704 A JP 2024010704A JP 2022112133 A JP2022112133 A JP 2022112133A JP 2022112133 A JP2022112133 A JP 2022112133A JP 2024010704 A JP2024010704 A JP 2024010704A
- Authority
- JP
- Japan
- Prior art keywords
- water
- dialysis
- dialysate
- fatigue
- hemodialysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001631 haemodialysis Methods 0.000 title claims abstract description 26
- 230000000322 hemodialysis Effects 0.000 title claims abstract description 26
- 239000000385 dialysis solution Substances 0.000 title abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 86
- 239000001257 hydrogen Substances 0.000 claims abstract description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 7
- 239000001301 oxygen Substances 0.000 abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 abstract description 7
- 239000000243 solution Substances 0.000 abstract description 7
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 description 58
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 206010016256 fatigue Diseases 0.000 description 31
- 238000001223 reverse osmosis Methods 0.000 description 22
- 238000005868 electrolysis reaction Methods 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 16
- 239000012528 membrane Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 8
- 229920005597 polymer membrane Polymers 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000012510 hollow fiber Substances 0.000 description 5
- 238000011045 prefiltration Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000005056 cell body Anatomy 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920006254 polymer film Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- -1 oxonium ions Chemical class 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920003934 Aciplex® Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229920003935 Flemion® Polymers 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 229920000557 Nafion® Polymers 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000005518 polymer electrolyte Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006833 reintegration Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- External Artificial Organs (AREA)
Abstract
Description
上述の電解モジュール7を備える図1に示す透析用水作製装置10を使用して、透析液を製造した。より具体的には、電解モジュールを備える電解水透析多人数用の透析用水作製装置(トリムメディカルインスティテュート社製、商品名:EW-SP754-HD)を用いて、逆浸透水を作製し、透析液調製装置(日機装社製、商品名:BHI、DRT32)と透析液供給装置(日機装社製、商品名:DAB40E)とを用いて、逆浸透水と透析原液とを混合した本実施例の透析液(溶存水素濃度が120~163ppb)を調製し、調製した透析液を透析装置(日機装社製、商品名:DCS27またはDCS100NX)へ供給した。
まず、慢性の血液透析患者(95人、平均透析期間:10.6年)に対して、透析当日、及び透析翌日の疲労感の有無について聞き取り調査を実施し、疲労感の観点から、患者を以下の3つのグループ(グループA~C)に分けた。
グループB:透析当日、及び透析翌日に疲労感あり(95人中の11.6%、11人)
グループC:疲労感なし(95人中の48.4%、46人)
2 原水
3 プレフィルター
4 軟水化装置
5 カーボンフィルター
7 電解モジュール
8 電解水タンク
10 透析用水作製装置
14 固体高分子膜
11 陽極
12 陰極
13 誘電体層
15 電解槽本体
16 導入路
17 処理水
18 送水路
19 溶存酸素水
20 電解槽
21 排水路
26 透析液調製装置
27 透析液
32 制御装置
36 逆浸透膜
37 逆浸透水タンク
40 透析装置
41 透析液導入路
43 ダイアライザー(血液浄化装置)
44 動脈側血液回路
45 静脈側血液回路
50 患者
Claims (2)
- 電解水素水を含有し、溶存水素濃度が100~200ppbであり、疲労感を抑制する活性を有することを特徴とする血液透析用の透析液。
- 前記疲労感が、血液透析に由来する継続的な疲労感であることを特徴とする請求項1に記載の血液透析用の透析液。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022112133A JP2024010704A (ja) | 2022-07-13 | 2022-07-13 | 血液透析用の透析液 |
US18/352,132 US20240016832A1 (en) | 2022-07-13 | 2023-07-13 | Dialysate for hemodialysis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022112133A JP2024010704A (ja) | 2022-07-13 | 2022-07-13 | 血液透析用の透析液 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2024010704A true JP2024010704A (ja) | 2024-01-25 |
Family
ID=89510932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022112133A Pending JP2024010704A (ja) | 2022-07-13 | 2022-07-13 | 血液透析用の透析液 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20240016832A1 (ja) |
JP (1) | JP2024010704A (ja) |
-
2022
- 2022-07-13 JP JP2022112133A patent/JP2024010704A/ja active Pending
-
2023
- 2023-07-13 US US18/352,132 patent/US20240016832A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240016832A1 (en) | 2024-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1119291C (zh) | 医疗用电解水的制造方法及利用该水作透析液的透析装置 | |
JP5901665B2 (ja) | 透析液調製用水の製造装置 | |
US9145318B2 (en) | Systems and methods for removing hydrogen peroxide from water purification systems | |
JP5714060B2 (ja) | 透析液調製用水の製造装置 | |
WO2014006740A1 (ja) | 透析液調製用水の製造装置 | |
JP5840248B2 (ja) | 透析液の製造装置 | |
JP6183832B2 (ja) | 酸化ストレス抑制型透析用剤およびその調製方法 | |
JP5940689B1 (ja) | 透析液調製用水の製造装置 | |
JP2010063629A (ja) | 透析装置 | |
EP3603691B1 (en) | Dialysate for hemodialysis | |
JP2015177911A (ja) | 透析液の製造装置 | |
CN109475674B (zh) | 透析液制造装置的清洗方法 | |
JP2024010704A (ja) | 血液透析用の透析液 | |
JP2016013349A (ja) | 透析液希釈用水素水製造装置 | |
JP6479140B2 (ja) | 透析液製造装置の洗浄方法 | |
JP7324904B1 (ja) | 水処理装置 | |
WO2020071075A1 (ja) | 透析液の製造装置 | |
RU2174411C2 (ru) | Способ приготовления диализирующего раствора | |
JPH09619A (ja) | 血液透析システムを洗浄する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220713 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220713 |
|
A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20220715 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221003 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230201 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230220 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230303 |